Although GLP-1 RAs mediate favorable effects in the setting of obesity, the benefits of GLP1-RAs are accompanied by conflicting results about bone health, particularly the risk of bone fractures and reduced bone mass density (378-380). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.